Abstract
Patients with an increased risk for thromboembolic or ischemic events, for instance with a mechanical heart valve, atrial fibrillation, or coronary stenosis, receive oral anticoagulants or antiplatelet drugs to prevent further events. The use of these drugs is associated with more bleeding events during surgery, and discontinuation of therapy requires an individual assessment of the balance between thromboembolic and bleeding risks. In order to overcome the loss of the preventive action of oral anticoagulants and antiplatelet drugs, patients are bridged by heparins or short acting glycoprotein IIb/IIIa inhibitors. Bridging is however only beneficial in specific subgroups of patients, and requires multidisciplinary clinical decision-making.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Nishimura R, Otto C, Bonow R, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease. JACC. 2017;70:252–89.
January C, Wann S, Alpert J, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199–267.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.
Kristensen S, Knuuti J, Saraste A, et al. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J. 2014;35:2383–431.
Guyatt G, Akl E, Crowther M, et al. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians. Evidence-based clinical practice guidelines. Chest. 2012;141:7S–47S.
Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010;31:2501–55.
Kernan W, Ovbiagele B, Black H, et al. on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014;45:2160–236.
Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e326S–50S.
Rechenmacher S, Fang JC. Bridging anticoagulation: Primum non Nocere. J Am Coll Cardiol. 2015;66:1392–403.
Steinberg BA, Peterson ED, Kim S, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation. 2015;131:488–94.
Parikh N, Cool J, Karas M, et al. Stroke Risk and Mortality in Patients With Ventricular Assist Devices. Stroke. 2016;47:2702–6.
Mehra MR, Goldstein DJ, Uriel N, et al. for the MOMENTUM 3 Investigators. Two-year outcomes with a magnetically levitated cardiac pump in heart failure. N Engl J Med. 2018;378:1386–95.
Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation. 2012;126:343–8.
Garcia D, Alexander JH, Wallentin L, et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014;124:3692–8.
Ayoub K, Nairooz R, Almomani A, et al. Perioperative heparin bridging in atrial fibrillation patients requiring temporary interruption of anticoagulation: evidence from meta-analysis. J Stroke Cerebrovasc Dis. 2016;25:2215–21.
Kim TH, Kim JY, Mun HS, et al. Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis. J Thromb Haemost. 2015;13:182–90.
Douketis J, Spyropoulos A, Kaatz S et al. for the BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823–33.
Siegal D, Yudin J, Kaatz S, et al. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126:1630–9.
Beyer-Westendorf J, Gelbricht V, Forster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014;35:1888–96.
Keeling D, Tait RC, Watson H, et al. Peri-operative management of anticoagulation and antiplatelet therapy. Br J Haematol. 2016;175:602–13.
Anastasiou I, Petousis S, Hamilos M. Current strategies for bridging dual antiplatelet therapy in patients requiring surgery. Interv Cardiol. 2015;7:137–48.
Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. The task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–54.
Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA), Boer C, Meesters M, Milojevic M, et al. 2017 EACTS/EACTA guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth. 2018;32:88–120.
Vanassche T, Lauw MN, Connolly SJ, Eikelboom JW. Heparin bridging in peri-procedural management of new oral anticoagulant: a bridge too far? Eur Heart J. 2014;35:1831–3.
Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251–6.
Savonitto S, D’Urbano M, Caracciolo M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ‘bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth. 2010;104:285–91.
Angiolillo DJ, Firstenberg MS, Price MJ, et al. BRIDGE investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307:265–74.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Colson, P. (2019). Bridging. In: von Heymann, C., Boer, C. (eds) Patient Blood Management in Cardiac Surgery. Springer, Cham. https://doi.org/10.1007/978-3-030-15342-7_8
Download citation
DOI: https://doi.org/10.1007/978-3-030-15342-7_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-15341-0
Online ISBN: 978-3-030-15342-7
eBook Packages: MedicineMedicine (R0)